Home/Pipeline/DOT

DOT

Treatment-Resistant Depression (TRD)

Pre-clinicalActive

Key Facts

Indication

Treatment-Resistant Depression (TRD)

Phase

Pre-clinical

Status

Active

Company

Motif Neurotech

About Motif Neurotech

Motif Neurotech is a private, pre-revenue medical device company pioneering a novel therapeutic brain-computer interface (BCI) for mental health. Its lead program targets treatment-resistant depression with a pea-sized, wirelessly powered implant (DOT) that stimulates the brain's Central Executive Network via a wearable hat, aiming to rebalance neural activity. Founded by CEO Jacob Robinson, PhD, the company leverages patent-pending magnetoelectric power transfer technology from Rice University and is building a patient registry while progressing toward clinical trials.

View full company profile

Therapeutic Areas

Psychiatry Neuroscience

Other Treatment-Resistant Depression (TRD) Drugs

Drug	Company	Phase	Status
CYC-126	Cyclerion Therapeutics	Phase 1	Active / Lead Candidate
FMP374	FundaMental Pharma	Preclinical	Active
R-107	Tasman Therapeutics	Phase 3	Active
GH001	GH Research	Phase 2b/3	Phase 2b completed; Phase 3 initiation planned for 2026
COMP360 Psilocybin Therapy	Compass Pathways	Phase 3	Active, Global Program
Ketamir-2 (Ketamir)	MIRA Pharmaceuticals	Phase 1	Active